- Home
- JAGX vs TCRT Comparison
JAGX vs TCRT Comparison
Compare JAGX & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JAGX
- TCRT
- Stock Information
- Founded
- JAGX 2013
- TCRT 1998
- Country
- JAGX United States
- TCRT United States
- Employees
- JAGX N/A
- TCRT N/A
- Industry
- JAGX Biotechnology: Pharmaceutical Preparations
- TCRT Biotechnology: Pharmaceutical Preparations
- Sector
- JAGX Health Care
- TCRT Health Care
- Exchange
- JAGX Nasdaq
- TCRT Nasdaq
- Market Cap
- JAGX 3.4M
- TCRT 3.8M
- IPO Year
- JAGX N/A
- TCRT N/A
- Fundamental
- Price
- JAGX $2.30
- TCRT $3.10
- Analyst Decision
- JAGX Strong Buy
- TCRT
- Analyst Count
- JAGX 1
- TCRT 0
- Target Price
- JAGX $60.00
- TCRT N/A
- AVG Volume (30 Days)
- JAGX 97.0K
- TCRT 57.8K
- Earning Date
- JAGX 08-12-2025
- TCRT 08-13-2025
- Dividend Yield
- JAGX N/A
- TCRT N/A
- EPS Growth
- JAGX N/A
- TCRT N/A
- EPS
- JAGX N/A
- TCRT N/A
- Revenue
- JAGX $11,552,000.00
- TCRT $11,000.00
- Revenue This Year
- JAGX $22.41
- TCRT $5,680,500.00
- Revenue Next Year
- JAGX $30.00
- TCRT N/A
- P/E Ratio
- JAGX N/A
- TCRT N/A
- Revenue Growth
- JAGX 13.93
- TCRT 83.33
- 52 Week Low
- JAGX $2.27
- TCRT $1.31
- 52 Week High
- JAGX $110.75
- TCRT $6.20
- Technical
- Relative Strength Index (RSI)
- JAGX 28.65
- TCRT 36.61
- Support Level
- JAGX $2.28
- TCRT $4.72
- Resistance Level
- JAGX $2.79
- TCRT $3.94
- Average True Range (ATR)
- JAGX 0.14
- TCRT 0.53
- MACD
- JAGX 0.09
- TCRT -0.28
- Stochastic Oscillator
- JAGX 3.92
- TCRT 1.01
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.